These data are consistent with the decreased serum expression of the CCR6 ligand, CCL20, in RA patients undergoing anti-TNF therapy (139), and suggest that TNF-blockade may induce rerouting of Th17 cells from inflamed tissues to peripheral blood. This evidence concerns the gene CCR6 and rheumatoid arthritis.